Cargando…

Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients

Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma cells. In the last decade, the introduction of novel targeted agents such as thalidomide, bortezomib, and lenalidomide has dramatically improved the clinical outcome of MM patients in bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Guo, Hongfeng, Zhou, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459627/
https://www.ncbi.nlm.nih.gov/pubmed/26082645
http://dx.doi.org/10.2147/OTT.S65762
_version_ 1782375248268623872
author Wang, Jing
Guo, Hongfeng
Zhou, Xin
author_facet Wang, Jing
Guo, Hongfeng
Zhou, Xin
author_sort Wang, Jing
collection PubMed
description Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma cells. In the last decade, the introduction of novel targeted agents such as thalidomide, bortezomib, and lenalidomide has dramatically improved the clinical outcome of MM patients in both the frontline and recurrent settings. Lenalidomide is a synthetic derivative of thalidomide, which has been shown to significantly improve overall survival, time to progression, and overall response rates in patients with MM. The China Food and Drug Administration approved the use of lenalidomide in patients with MM in 2013. In a Phase II trial, lenalidomide plus low-dose dexamethasone was associated with a high response rate and acceptable safety profile in heavily pretreated Chinese patients with relapsed/refractory MM, including those with renal impairment and IgD subtype. However, lenalidomide will remain as a second-line antimyeloma drug in the near future because of its high price and the policy of health insurance reimbursement in People’s Republic of China. In this review, we summarize the clinical utility and patient considerations in the use of lenalidomide for MM in Chinese patients. Further studies with larger sample sizes are required to investigate the better quality, longer duration, and more clinically meaningful outcomes of lenalidomide in the treatment of MM in Chinese patients.
format Online
Article
Text
id pubmed-4459627
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44596272015-06-16 Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients Wang, Jing Guo, Hongfeng Zhou, Xin Onco Targets Ther Review Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma cells. In the last decade, the introduction of novel targeted agents such as thalidomide, bortezomib, and lenalidomide has dramatically improved the clinical outcome of MM patients in both the frontline and recurrent settings. Lenalidomide is a synthetic derivative of thalidomide, which has been shown to significantly improve overall survival, time to progression, and overall response rates in patients with MM. The China Food and Drug Administration approved the use of lenalidomide in patients with MM in 2013. In a Phase II trial, lenalidomide plus low-dose dexamethasone was associated with a high response rate and acceptable safety profile in heavily pretreated Chinese patients with relapsed/refractory MM, including those with renal impairment and IgD subtype. However, lenalidomide will remain as a second-line antimyeloma drug in the near future because of its high price and the policy of health insurance reimbursement in People’s Republic of China. In this review, we summarize the clinical utility and patient considerations in the use of lenalidomide for MM in Chinese patients. Further studies with larger sample sizes are required to investigate the better quality, longer duration, and more clinically meaningful outcomes of lenalidomide in the treatment of MM in Chinese patients. Dove Medical Press 2015-06-02 /pmc/articles/PMC4459627/ /pubmed/26082645 http://dx.doi.org/10.2147/OTT.S65762 Text en © 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Wang, Jing
Guo, Hongfeng
Zhou, Xin
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
title Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
title_full Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
title_fullStr Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
title_full_unstemmed Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
title_short Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
title_sort clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in chinese patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459627/
https://www.ncbi.nlm.nih.gov/pubmed/26082645
http://dx.doi.org/10.2147/OTT.S65762
work_keys_str_mv AT wangjing clinicalutilityandpatientconsiderationintheuseoflenalidomideformultiplemyelomainchinesepatients
AT guohongfeng clinicalutilityandpatientconsiderationintheuseoflenalidomideformultiplemyelomainchinesepatients
AT zhouxin clinicalutilityandpatientconsiderationintheuseoflenalidomideformultiplemyelomainchinesepatients